REGISTER
MedJ at ESMO 2025 with Dr. Philippe Merle
New research helps clarify the debate around MedJ at ESMO 2025 with Dr. Philippe Merle. The summary connects evidence on ESMO, MD, TRIPLET with who may benefit, what risks matter most, and how practice could change.

Philippe Merle, MD, Université Claude Bernard Lyon 1, France

Unveiling the TRIPLET HCC Study – Hepatocellular Carcinoma Triple Therapy Demonstrates Encouraging Efficacy Signals, Reshaping the Current Treatment Landscape!

0
0
Loading